© Reuters. Aspen Aerogels And 28 Stocks Moving Premarket
Gainers
- Revelation Biosciences, Inc. (: REVB) rose 149.3% to $1.56 in pre-market trading after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
- 374Water, Inc. (NASDAQ: SCWO) rose 58.5% to $4.47 in pre-market trading.
- Aspen Aerogels, Inc. (NYSE: ASPN) rose 57.7% to $13.30 in pre-market trading after the company announced its decision not to proceed with concurrent public offerings of common stock and green convertible senior notes due 2027.
- Color Star Technology Co., Ltd. (NASDAQ: CSCW) rose 35.9% to $0.1784 in pre-market trading.
- Codex DNA, Inc. (NASDAQ: DNAY) rose 27.6% to $2.45 in pre-market trading after dipping 16% on Wednesday.
- AIM ImmunoTech Inc. (NYSE: AIM) rose 22.9% to $1.02 in pre-market trading.
- Adagene Inc. (NASDAQ: ADAG) rose 19.2% to $2.48 in pre-market trading after the company reported authorization of $10 million buyback program.
- 2U, Inc. (NASDAQ: TWOU) shares rose 13.6% to $10.56 in pre-market trading after declining over 4% on Tuesday.
- Applied Therapeutics, Inc. (NASDAQ: APLT) rose 13.1% to $0.9950 in pre-market trading. Applied Therapeutics recently announced a $30 million public offering of common stock and warrants.
- AIM ImmunoTech Inc. (NYSE: AIM) shares rose 11.8% to $0.95 in pre-market trading.
- Mullen Automotive, Inc. (NASDAQ: MULN) rose 11.5% to $1.26 in pre-market trading after declining 7% on Wednesday. Mullen Automotive recently announced it has filed over 130 patents in 24 countries for the Mullen FIVE EV crossover program.
- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) rose 10.7% to $0.31 in pre-market trading.
- First Wave BioPharma, Inc. (NASDAQ: FWBI) shares rose 9.3% to $0.3499 in pre-market trading.
- Quanergy Systems, Inc. (NYSE: QNGY) rose 9% to $0.43 in pre-market trading.
- Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 8.7% to $0.1629 in pre-market trading.
Don’t forget to check out our premarket coverage here .
Losers
- Akerna Corp. (NASDAQ: KERN) fell 35.6% to $0.1892 in pre-market trading after dropping around 4% on Wednesday.
- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) fell 24.7% to $0.1920 in pre-market trading. Allena Pharmaceuticals shares jumped 114% on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
- Duck Creek Technologies, Inc. (NASDAQ: DCT) fell 19.1% to $14.90 in pre-market trading after the company reported Q3 results and lowered FY22 revenue guidance.
- Brickell Biotech, Inc. (NASDAQ: BBI) fell 18.6% to $0.14 in pre-market trading after jumping around 48% on Wednesday.
- Hyperfine, Inc. (NASDAQ: HYPR) shares fell 16.3% to $2.26 in pre-market trading. Hyperfine appointed Scott Huennekens as Interim President & CEO.
- Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 14.2% to $0.8415 in pre-market trading. Evofem Biosciences recently announced an agreement with a pharmacy benefit manager.
- COMSovereign Holding Corp. (NASDAQ: COMS) shares fell 13.8% to $0.2140 in pre-market trading after jumping over 60% on Wednesday.
- Femasys Inc. (NASDAQ: FEMY) fell 13% to $2.40 in pre-market trading after gaining around 7% on Wednesday.
- Agile Therapeutics, Inc. (NASDAQ: AGRX) fell 11% to $1.37 in pre-market trading after the company filed for an offering of up to approximately 15.75 million shares
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) fell 11% to $0.3382 in pre-market trading after gaining around 9% on Wednesday.
- The Very Good Food Company Inc.. (NASDAQ: VGFC) shares fell 10.2% to $0.2350 in pre-market trading. The Very Good Food Company recently announced an agreement with Meijer for its 'Original Ribz' and 'Very Good Steak' products to be offered at 180 Meijer locations.
- Can-Fite BioPharma Ltd. (NYSE: CANF) fell 7.8% to $0.94 in pre-market trading. Can-Fite BioPharma shares jumped over 15% on Wednesday after the company announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) fell 7.7% to $2.53 in pre-market trading. NeuroSense Therapeutics recently reported results from a stage III ALS Biomarker study evaluating PrimeC.
- Connect Biopharma Holdings Limited (NASDAQ: CNTB) shares fell 7.2% to $0.9186 in pre-market trading after gaining around 9% on Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read at Benzinga
Read the original article on Benzinga
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.